Translation-X
Translation-X is a biotech startup developing brain-penetrant MNK inhibitors to treat core symptoms of autism spectrum disorder. The company focuses on rare genetic conditions initially, using a phenotyping approach to expand its target population. Its novel therapeutic approach targets dysregulated mRNA translation to restore normal neural function.
Funding Round: Seed
Funding Amount: €160K
Date: 02-Oct-2024
Investors: Venture Kick
Markets: Biotech, Pharmaceutical, Healthtech
HQ: Basel, Basel-Stadt, Switzerland
Founded: 2022
Website: https://www.trx-therapeutics.com/
Leave a Comment
Comments
No comments yet.